



SHREE CEMENT

Cost efficiencies to aid performance

- Volume-led (+23%) revenue growth of 15% YoY in Q3 as realisations fell due to weak pricing in key regions
- Cost control commendable (+1% YoY); efforts to improve efficiencies likely to yield results in the short/medium term
- Current valuations fair at 14x FY25E EV/EBITDA; maintain HOLD with an unchanged TP of Rs 24,656

Volume-driven growth: SRCM reported 15% YoY and 8% QoQ revenue growth to Rs 40.7bn in Q3FY23, fully attributed to cement revenue (no segmental income). Volumes grew 23% YoY and 8% QoQ to 8.03mt, including clinker sales of 0.3mt. Realisations fell 7% YoY (flat QoQ) to Rs 5,065/t due to weak pricing in key regions.

Cost control commendable: Operating cost increased only 1% YoY to Rs 4,184/t. Energy cost including raw materials grew 29% YoY (-7% QoQ) to Rs 1,967/t due to higher fuel cost (imported coal and pet-coke) which rose 32% YoY (-2% QoQ). Logistics cost was flattish (+1% YoY, +2% QoQ) at Rs 1,174/t despite the busyseason surcharge. SRCM intends to increase rail share to rationalise costs further. Other expenditure grew only 7% YoY to Rs 6.1bn despite the strong volume gains.

EBITDA contracts: EBITDA fell 14% YoY to Rs 7.1bn (+35% QoQ) and operating margin dropped sharply by 585bps YoY to 17% (+360bps QoQ) due to volume driven growth hit by realisations. Cement EBITDA/t contracted 30% YoY to Rs 881/t (+26% QoQ) and PAT declined 44% YoY to Rs 2.8bn (+46% QoQ).

Aggressive capex plans for FY24/FY25: Commissioning of the 3mt grinding unit in Purulia, West Bengal, is targeted by Jun'24; the 3mt integrated cement unit at Nawalgarh, Rajasthan, by Q3FY24; and the 3mt integrated cement unit in Guntur, Andhra Pradesh, by Q2FY25. The goal is to have 80mt of capacity (organic) by 2030 from 46mt now.

Maintain HOLD with a positive bias: SRCM has quadrupled its capacity to 40mtpa over FY11-FY20 and further to 46mtpa in FY23 YTD, gaining a multi-regional presence. Strong cash flows have helped fund growth and preserve financial and operational levers over the long term. Opex too is better than industry and we forecast healthy ROE/ROCE of ~14% in FY25. However, current valuations of 14x FY25E EV/EBITDA fully factor in the performance. We retain our TP of Rs 24,656, set at 15x FY25E – 2.25x over the industry replacement cost. Maintain HOLD.

11 February 2023

Milind Raginwar | Yash Thakur research@bobcaps.in

Key changes

Cement

Target	Rating				
<►	<►				
/Price	SRCM IN/Rs 23,971				
et cap	US\$ 10.5bn				
loat	37%				
V	US\$ 11.4mn				
high/low	Rs 26,340/Rs 17,865				
oter/FPI/DII	63%/13%/12%				
	/Price //Price tit cap loat DV high/low obter/FPI/DII	//Price SRCM IN/Rs 23,971 et cap US\$ 10.5bn loat 37% DV US\$ 11.4mn high/low Rs 26,340/Rs 17,865			

Source: NSE | Price as of 10 Feb 2023

Key financials

Y/E 31 Mar	FY22A	FY23E	FY24E
Total revenue (Rs mn)	139,118	162,446	191,300
EBITDA (Rs mn)	32,201	28,227	40,321
Adj. net profit (Rs mn)	23,668	11,356	20,460
Adj. EPS (Rs)	655.3	314.4	566.5
Consensus EPS (Rs)	655.3	436.0	681.0
Adj. ROAE (%)	14.6	6.4	10.8
Adj. P/E (x)	36.6	76.2	42.3
EV/EBITDA (x)	23.9	27.6	19.2
Adj. EPS growth (%)	2.4	(52.0)	80.2

Source: Company, Bloomberg, BOBCAPS Research

Stock performance



Source: NSE





Earnings call highlights

- Capacity utilisation improved to 72% in Q3FY23 from 61% in the year-ago quarter.
- In terms of pricing, management indicated that current cement prices are equal to Q3FY23 exit prices.
- Premium product share was at 7% of total sales in Q3 unchanged for the last few quarters. SRCM expects this proportion to rise to ~15% over the next 3-4 quarters. The company will focus on strengthening its position in the existing portfolio and on introducing new brands to the market.
- Management indicated that fuel cost has reduced from Rs 2.83/kcal in Q2FY23 to Rs 2.53/kcal in Q3FY23 and is currently at ~Rs 2.35/kcal. Management expects a further reduction, aiding improvement in EBITDA/t to Rs 1,000/t in Q4.
- The fuel mix in Q3 was 58% pet coke, 28% coal and ~14% alternate fuel. The trade mix has been stable at 78%-80% over the past three quarters, and lead distance stood at ~450km (+5km YoY, +9km QoQ). Management intends to increase rail dispatches from the current 12%.
- Commissioning of the 3mt grinding unit in Purulia, West Bengal, is targeted by Jun'24; the 3mt integrated cement unit at Nawalgarh, Rajasthan, by Q3FY24; and the 3mt integrated cement unit in Guntur, Andhra Pradesh, by Q2FY25.
- SRCM aims to reach 80mt of capacity by 2030 (organically). Any potential inorganic opportunity would add to this plan.
- The company added 84MW of solar power plants in FY23. Another 42MW is to be added in the next two quarters. The share of green energy in total power consumption increased to 53% in Q3 against 47% in the year-ago period. SRCM intends to raise the use of agricultural and industrial waste in its plants and also improve its thermal substitution rate from 3% (FY22) to 15% (FY24).
- Capex in 9MFY23 was Rs 22bn, including subsidiaries. In Q4FY23, management expect to spend close to Rs 7bn-8bn, taking the total to ~Rs 29bn in FY23. For FY24, spends are envisaged to be in the range of Rs 33bn-35bn.
- Gross debt stood at ~Rs 83bn and net debt at Rs 57bn end 3QFY23.

Fig 1 – Key metrics

(Rs)	Q3FY23	Q3FY22	YoY (%)	Q2FY23	QoQ (%)
Volumes (mt)	8.0	6.6	22.6	7.5	7.7
Cement realisations (Rs/mt)	5,065	5,422	(6.6)	5,071	(0.1)
Operating costs (Rs/mt)	4,184	4,162	0.5	4,369	(4.2)
EBITDA (Rs/mt)	881	1,260	(30.1)	701	25.7

Source: Company, BOBCAPS Research |



Fig 2 – Quarterly performance

(Rs mn)	Q3FY23	Q3FY22	YoY (%)	Q2FY23	QoQ (%)
Net Sales	40,688	35,518	14.6	37,806	7.6
Expenditure					
Change in stock	(326)	(908)	(64.0)	691	(147.2)
Raw material	3,100	2,831	9.5	2,859	8.4
Purchased products	57	1,934	(97.1)	146	-
Power & fuel	13,027	8,079	61.3	12,270	6.2
Freight	9,429	7,616	23.8	8,561	10.1
Employee costs	2,179	1,965	10.9	2,097	3.9
Other expenditure	6,143	5,745	6.9	5,955	3.1
Total Operating Expenses	33,608	27,263	23.3	32,579	3.2
EBITDA	7,080	8,255	(14.2)	5,227	35.4
EBITDA margin (%)	17.4	23.2	(584bps)	13.8	357bps
Other Income	1,612	1,101	46.4	1,569	2.8
Interest	714	551	29.5	676	5.7
Depreciation	4,136	2,521	64.0	3,628	14.0
PBU	3,842	6,284	(38.9)	2,493	54.1
Non-recurring items	0	0	-	0	-
PBU (after non-recurring items)	3,842	6,284	(38.9)	2,493	54.1
Tax	1,074	1,364	(21.3)	597	80.0
Reported PAT	2,768	4,920	(43.7)	1,896	46.0
Adjusted PAT	2,768	4,920	(43.7)	1,896	46.0
NPM (%)	6.8	13.9	(705bps)	5.0	179bps
Adjusted EPS (Rs)	77	136	(43.7)	53	46.0

Source: Company, BOBCAPS Research




Fig 3 – New capacities to ensure sustained volume gains



Source: Company, BOBCAPS Research

Fig 5 – Strong cost control to aide EBITDA/t gains



Source: Company, BOBCAPS Research

Fig 7 – Flattish logistics cost a key positive surprise





Fig 4 – Realisations to remain volatile



Growth (R) (%) (Rs/mt) Operating costs 5,000 40 4,000 28 3,000 16 2,000 4 1,000 (8) 0 (20) Q4FY20 Q1FY22 Q2FY22 Q3FY22 Q4FY22 Q1FY23 Q2FY23 Q3FY23 Q1FY21 Q2FY21 Q3FY21 Q4FY21 Q3FY20

Source: Company, BOBCAPS Research




Fig 8 – Energy cost expected to soften further

Source: Company, BOBCAPS Research

Fig 6 – Operating cost control commendable



Valuation methodology

SRCM has quadrupled its capacity to 40mtpa over FY11-FY20 and further to 46mtpa in FY23 YTD, gaining a multi-regional presence, with volume growth keeping abreast of capacity addition. Strong cash flows have helped fund its expansion drive and preserve balance sheet health over the long term. Opex too is currently better than peers and we forecast healthy ROE/ROCE of ~14% in FY25.

However, current valuations of 14x FY25E EV/EBITDA fully factor in these positives. We continue to value the stock at 15x FY25E EV/EBITDA for an unchanged TP of Rs 24,656, implying a replacement cost of Rs 16.8bn/mt (2.25x the industry average). Despite the high premium, our TP carries only 3% upside Maintain HOLD.

Fig 9 – Key assumptions

Parameter	FY22	FY23E	FY24E	FY25E
Volumes (mt)	27.1	31.1	35.6	39.6
Realisations (Rs/mt)	5,052	5,115	5,268	5,426
Operating costs (Rs/mt)	3,856	4,239	4,161	4,168
EBITDA/mt (Rs)	1,182	901	1,126	1,275

Source: Company, BOBCAPS Research

Fig 10 – Valuation summary

(Rs mn)	FY25E
Target EV/EBITDA (x)	15
EBITDA	50,638
Target EV	7,81,849
Total EV	7,81,849
Net debt	(1,08,718)
Target market capitalisation	8,90,567
Target price (Rs/sh)	24,656
Weighted average shares (mn)	36
Source: BOBCAPS Research	

Fig 11 – Peer comparison

Ticker	Rating	ТР	E١	V/EBITDA (x)	EV	/tonne (US	\$)		ROE (%)			ROCE (%)	
TICKET	Raung	(Rs)	FY23E	FY24E	FY25E	FY23E	FY24E	FY25E	FY23E	FY24E	FY25E	FY23E	FY24E	FY25E
SRCM IN	HOLD	24,656	26.6	18.5	14.4	199	197	193	6.4	10.8	13.6	9.2	14.6	18.0
DALBHARA IN	HOLD	1,835	17.7	14.6	11.5	134	141	138	4.4	7.0	10.4	5.3	7.6	10.4
ACC IN	HOLD	2,090	20.8	14.9	8.9	102	102	94	5.3	7.0	11.3	7.0	9.4	14.9

Source: BOBCAPS Research

Key risks

- SRCM is trying to diversify into new regions that have higher supply pressure. Hence, pricing pressure may impact its performance more than estimated.
- Aggressive capacity addition can be detrimental in the event of an economic slowdown.
- Faster-than-expected easing of key raw material cost is an upside risk.



Sector recommendation snapshot

Company	Ticker	Market Cap (US\$ bn)	Price (Rs)	Target (Rs)	Rating
ACC	ACC IN	4.3	1,880	2,090	HOLD
Ambuja Cement	ACEM IN	8.7	361	387	HOLD
Dalmia Bharat	DALBHARA IN	4.6	1,939	1,835	HOLD
JK Cement	JKCE IN	2.6	2,803	3,371	BUY
JK Lakshmi Cement	JKLC IN	1.1	758	551	SELL
Orient Cement	ORCMNT IN	0.3	123	140	HOLD
Shree Cement	SRCM IN	10.5	23,971	24,656	HOLD
Star Cement	STRCEM IN	0.6	113	138	BUY
The Ramco Cements	TRCL IN	2.1	734	534	SELL
Ultratech Cement	UTCEM IN	25.2	7,206	8,310	BUY

Source: BOBCAPS Research, NSE | Price as of 10 Feb 2023



Financials

Y/E 31 Mar (Rs mn)	FY21A	FY22A	FY23E	FY24E	FY25E
Total revenue	123,160	139,118	162,446	191,300	218,529
EBITDA	36,943	32,201	28,227	40,321	50,638
Depreciation	(11,399)	(10,365)	(14,014)	(15,374)	(16,813
EBIT	32,728	31,389	17,701	30,148	41,593
Net interest inc./(exp.)	(2,471)	(2,178)	(2,592)	(2,864)	(3,148
Other inc./(exp.)	7,184	9,553	3,488	5,200	7,769
Exceptional items	0	0	0	0	(
EBT	30,257	29,211	15,109	27,284	38,44
Income taxes	(7,138)	(5,543)	(3,753)	(6,823)	(9,617
Extraordinary items	0	0	0	0	(
Min. int./Inc. from assoc.	0	0	0	0	(
Reported net profit	23,119	23,668	11.356	20,460	28,82
Adjustments	0	0	0	0	
Adjusted net profit	23,119	23,668	11,356	20,460	28,82
	-, -	.,	,	.,	
Balance Sheet					
Y/E 31 Mar (Rs mn)	FY21A	FY22A	FY23E	FY24E	FY25
Accounts payables	7,858	17,853	12,726	14,987	17,12
Other current liabilities	22,343	23,307	30,808	34,256	37,14
Provisions	43	57	57	57	5
Debt funds	27,562	20,142	23,563	26,037	28,61
Other liabilities	(7,773)	(6,609)	(7,164)	(7,770)	(8,431
Equity capital	361	361	361	361	36
Reserves & surplus	152,140	172,348	180,647	198,050	223,82
Shareholders' fund	152,501	172,709	181,008	198,411	224,18
Total liab. and equities	202,533	227,459	240,998	265,978	298,69
Cash and cash eq.	112,604	116,642	110,211	117,877	137,33
Accounts receivables	4,859	5,957	7,297	8,990	10,72
Inventories	14,772	21,614	25,544	30,435	35,18
Other current assets	18,673	20,303	22,333	22,847	23,37
Investments	0	0	0	0	
Net fixed assets	37,702	46,887	43,028	43,334	38,20
CWIP	13,448	15,559	32,059	41,937	53,29
Intangible assets	475	497	527	558	59
Deferred tax assets, net	0	0	0	0	(
Other assets	0	0	0	0	(
Total assets	202,533	227,458	240,998	265,978	298,69
Cash Flows		51/00 4	51/005	51/045	51/05
Y/E 31 Mar (Rs mn)	FY21A	FY22A	FY23E	FY24E	FY25
Cash flow from operations	43,507	35,924	19,481	33,839	43,00
Capital expenditures	(9,928)	(21,154)	(26,685)	(25,590)	(23,073
Change in investments	(21,352)	(4,953)	7,888	(9,707)	(10,478
Other investing cash flows	0	0	0	(25.207)	(22 554
Cash flow from investing	(31,279)	(26,108)	(18,797)	(35,297)	(33,551
Equities issued/Others	0	0	0	0	0.50
Debt raised/repaid	(11,228)	(7,420)	3,421	2,474	2,58
Interest expenses	0	0	0	0	(0.057
Dividends paid	0	(3,788)	(2,649)	(3,057)	(3,057
Other financing cash flows	17	477	0	(592)	(476
Cach flow from financing	(11 211)	(40 794)	770		

Y/E 31 Mar (Rs)	FY21A	FY22A	FY23E	FY24E	FY25E
Reported EPS	640.1	655.3	314.4	566.5	798.2
Adjusted EPS	640.1	655.3	314.4	566.5	798.2
Dividend per share	0.0	104.9	72.3	72.3	72.3
Book value per share	4,222.4	4,781.9	5,011.7	5,493.5	6,207.1
Valuations Ratios					
Y/E 31 Mar (x)	FY21A	FY22A	FY23E	FY24E	FY25E
EV/Sales	6.3	5.5	4.8	4.0	3.5
EV/EBITDA	21.1	23.9	27.6	19.2	14.9
Adjusted P/E	37.4	36.6	76.2	42.3	30.0
P/BV	5.7	5.0	4.8	4.4	3.9
DuPont Analysis					
Y/E 31 Mar (%)	FY21A	FY22A	FY23E	FY24E	FY25E
Tax burden (Net profit/PBT)	76.4	81.0	75.2	75.0	75.0
Interest burden (PBT/EBIT)	92.4	93.1	85.4	90.5	92.4
EBIT margin (EBIT/Revenue)	26.6	22.6	10.9	15.8	19.0
Asset turnover (Rev./Avg TA)	63.4	64.7	69.4	75.5	77.4
Leverage (Avg TA/Avg Equity)	1.4	1.3	1.3	1.3	1.3
Adjusted ROAE	16.4	14.6	6.4	10.8	13.6
Ratio Analysis					
Y/E 31 Mar	FY21A	FY22A	FY23E	FY24E	FY25E
YoY growth (%)					
Revenue	5.6	13.0	16.8	17.8	14.2
EBITDA	7.6	(12.8)	(12.3)	42.8	25.6
Adjusted EPS	47.3	2.4	(52.0)	80.2	40.9
Profitability & Return ratios (%					
EBITDA margin	30.0	23.1	17.4	21.1	23.2
EBIT margin	26.6	22.6	10.9	15.8	19.0
Adjusted profit margin	18.8	17.0	7.0	10.7	13.2
Adjusted ROAE	16.4	14.6	6.4	10.8	13.6
ROCE	19.7	17.5	9.2	14.6	18.0
Working capital days (days)					
Receivables	14	16	16	17	18
Inventory	44	57	57	58	59
	33	61	35	36	37
Payables					
Payables Ratios (x)					
Ratios (x)	1.1	1.1	1.2	1.2	1.3
	5.0	4.0	3.8	3.7	1.3 3.8
Ratios (x) Gross asset turnover					

Source: Company, BOBCAPS Research | Note: TA = Total Assets

Cash flow from financing

Chg in cash & cash eq.

Closing cash & cash eq.

(11,211)

112,604

1,016

(10,731)

116,642

(915)

772

1,456

110,210

(583)

(2,041)

117,877

(476) 8,981

137,335



NOT FOR DISTRIBUTION, DIRECTLY OR INDIRECTLY, IN OR INTO THE UNITED STATES OF AMERICA ("US") OR IN OR INTO ANY OTHER JURISDICTION IF SUCH AN ACTION IS PROHIBITED BY APPLICABLE LAW.

Disclaimer

Recommendation scale: Recommendations and Absolute returns (%) over 12 months

BUY – Expected return >+15%

HOLD - Expected return from -6% to +15%

SELL - Expected return <-6%

Note: Recommendation structure changed with effect from 21 June 2021

Our recommendation scale does not factor in short-term stock price volatility related to market fluctuations. Thus, our recommendations may not always be strictly in line with the recommendation scale as shown above.

Ratings and Target Price (3-year history): SHREE CEMENT (SRCM IN)



B - Buy, H - Hold, S - Sell, A - Add, R - Reduce

Analyst certification

The research analyst(s) authoring this report hereby certifies that (1) all of the views expressed in this research report accurately reflect his/her personal views about the subject company or companies and its or their securities, and (2) no part of his/her compensation was, is, or will be, directly or indirectly, related to the specific recommendation(s) or view(s) in this report. Analysts are not registered as research analysts by FINRA and are not associated persons of BOB Capital Markets Limited (BOBCAPS).

General disclaimers

BOBCAPS is engaged in the business of Stock Broking and Investment Banking. BOBCAPS is a member of the National Stock Exchange of India Limited and BSE Limited and is also a SEBI-registered Category I Merchant Banker. BOBCAPS is a wholly owned subsidiary of Bank of Baroda which has its various subsidiaries engaged in the businesses of stock broking, lending, asset management, life insurance, health insurance and wealth management, among others.

BOBCAPS's activities have neither been suspended nor has it defaulted with any stock exchange authority with whom it has been registered in the last five years. BOBCAPS has not been debarred from doing business by any stock exchange or SEBI or any other authority. No disciplinary action has been taken by any regulatory authority against BOBCAPS affecting its equity research analysis activities.

BOBCAPS has obtained registration as a Research Entity under SEBI (Research Analysts) Regulations, 2014, having registration No.: INH000000040 valid till 03 February 2025. BOBCAPS is also a SEBI-registered intermediary for the broking business having SEBI Single Registration Certificate No.: INZ000159332 dated 20 November 2017. BOBCAPS CIN Number: U65999MH1996GOI098009.

BOBCAPS prohibits its analysts, persons reporting to analysts, and members of their households from maintaining a financial interest in the securities or derivatives of any companies that the analysts cover. Additionally, BOBCAPS prohibits its analysts and persons reporting to analysts from serving as an officer, director, or advisory board member of any companies that the analysts cover.

Our salespeople, traders, and other professionals may provide oral or written market commentary or trading strategies to our clients that reflect opinions contrary to the opinions expressed herein, and our proprietary trading and investing businesses may make investment decisions that are inconsistent with the recommendations expressed herein. In reviewing these materials, you should be aware that any or all of the foregoing, among other things, may give rise to real or potential conflicts of interest. Additionally, other important information regarding our relationships with the company or companies that are the subject of this material is provided herein.

This material should not be construed as an offer to sell or the solicitation of an offer to buy any security in any jurisdiction We are not soliciting any action based on this material. It is for the general information of BOBCAPS's clients. It does not constitute a personal recommendation or take into account the particular investment objectives, financial situations, or needs of individual clients. Before acting on any advice or recommendation in this material, clients should consider whether it is suitable for their particular circumstances and, if necessary, seek professional advice. BOBCAPS research reports follow rules laid down by Securities and Exchange Board of India and individuals employed as research analysts are separate from other employees who are performing sales trading, dealing, corporate finance advisory or any other activity that may affect the independence of its research reports.

The price and value of the investments referred to in this material and the income from them may go down as well as up, and investors may realize losses on any investments. Past performance is not a guide for future performance, future returns are not guaranteed and a loss of original capital may occur. BOBCAPS does not provide tax advice to its clients, and all investors are strongly advised to consult with their tax advisers regarding any potential investment in certain transactions — including those involving futures, options, and other derivatives as well as non-investment-grade securities — that give rise to substantial risk and are not suitable for all investors. The material is based on information that we consider reliable, but we do not represent that it is accurate or complete, and it should not be relied on as such. Opinions expressed are our current opinions as of the date appearing on this material only. We endeavour to update on a reasonable basis the information discussed in this material, but regulatory, compliance, or other reasons may prevent us from doing so.

SHREE CEMENT



We and our affiliates, officers, directors, and employees, including persons involved in the preparation or issuance of this material, may from time to time have "long" or "short" positions in, act as principal in, and buy or sell the securities or derivatives thereof of companies mentioned herein and may from time to time add to or dispose of any such securities (or investment). We and our affiliates may assume an underwriting commitment in the securities of companies discussed in this document (or in related investments), may sell them to or buy them from customers on a principal basis, and may also perform or seek to perform investment banking or advisory services for or relating to these companies and may also be represented in the supervisory board or any other committee of these companies.

For the purpose of calculating whether BOBCAPS and its affiliates hold, beneficially own, or control, including the right to vote for directors, one per cent or more of the equity shares of the subject company, the holdings of the issuer of the research report is also included.

BOBCAPS and its non-US affiliates may, to the extent permissible under applicable laws, have acted on or used this research to the extent that it relates to non-US issuers, prior to or immediately following its publication. Foreign currency denominated securities are subject to fluctuations in exchange rates that could have an adverse effect on the value or price of or income derived from the investment. In addition, investors in securities such as ADRs, the value of which are influenced by foreign currencies, effectively assume currency risk. In addition, options involve risks and are not suitable for all investors. Please ensure that you have read and understood the Risk disclosure document before entering into any derivative transactions.

No part of this material may be (1) copied, photocopied, or duplicated in any form by any means or (2) redistributed without BOBCAPS's prior written consent.

Company-specific disclosures under SEBI (Research Analysts) Regulations, 2014

The research analyst(s) or his/her relatives do not have any material conflict of interest at the time of publication of this research report.

BOBCAPS or its research analyst(s) or his/her relatives do not have any financial interest in the subject company. BOBCAPS or its research analyst(s) or his/her relatives do not have actual/beneficial ownership of one per cent or more securities in the subject company at the end of the month immediately preceding the date of publication of this report.

The research analyst(s) has not received any compensation from the subject company or third party in the past 12 months in connection with research report/activities. Compensation of the research analyst(s) is not based on any specific merchant banking, investment banking or brokerage service transactions.

BOBCAPS or its research analyst(s) is not engaged in any market making activities for the subject company.

The research analyst(s) has not served as an officer, director or employee of the subject company.

BOBCAPS or its associates may have material conflict of interest at the time of publication of this research report.

BOBCAPS's associates may have financial interest in the subject company. BOBCAPS's associates may hold actual / beneficial ownership of one per cent or more securities in the subject company at the end of the month immediately preceding the date of publication of this report.

BOBCAPS or its associates may have managed or co-managed a public offering of securities for the subject company or may have been mandated by the subject company for any other assignment in the past 12 months.

BOBCAPS may have received compensation from the subject company in the past 12 months. BOBCAPS may from time to time solicit or perform investment banking services for the subject company. BOBCAPS or its associates may have received compensation from the subject company in the past 12 months for services in respect of managing or co-managing public offerings, corporate finance, investment banking or merchant banking, brokerage services or other advisory services in a merger or specific transaction. BOBCAPS or its associates may have received compensation for products or services other than investment banking or merchant banking or brokerage services from the subject company in the past 12 months.

Other disclaimers

BOBCAPS and MAYBANK (as defined below) make no representation or warranty, express or implied, as to the accuracy or completeness of any information obtained from third parties and expressly disclaim the merchantability, suitability, quality and fitness of this report. The information in this report has not been independently verified, is provided on an "as is" basis, should not be relied on by you in connection with any contract or commitment, and should not be used as a substitute for enquires, procedures and advice which ought to be undertaken by you. This report also does not constitute an offer or solicitation to buy or sell any securities referred to here in and you should not construe this report as investment advice. All opinions and estimates contained in this report constitute BOBCAPS's judgment as of the date of this report and are subject to change without notice, and there is no obligation on BOBCAPS or MAYBANK to update this report upon issuance. This report and the information contained herein may not be reproduced, redistributed, disseminated or copied by any means without the prior consent of BOBCAPS and MAYBANK.

To the full extent permitted by law neither BOBCAPS, MAYBANK nor any of their respective affiliates, nor any other person, accepts any liability howsoever arising, whether in contract, tort, negligence, strict liability or any other basis, including without limitation, direct or indirect, special, incidental, consequential or punitive damages arising from any use of this report or the information contained herein. By accepting this report, you agree and undertake to fully indemnify and hold harmless BOBCAPS and MAYBANK from and against claims, charges, actions, proceedings, losses, liabilities, damages, expenses and demands (collectively, the "Losses") which BOBCAPS and/or MAYBANK may incur or suffer in any jurisdiction including but not limited to those Losses incurred by BOBCAPS and/or MAYBANK as a result of any proceedings or actions brought against them by any regulators and/or authorities, and which in any case are directly or indirectly occasioned by or result from or are attributable to anything done or omitted in relation to or arising from or in connection with this report.

Distribution into the United Kingdom ("UK"):

This research report will only be distributed in the United Kingdom, in accordance with the applicable laws and regulations of the UK, by Maybank Securities (London) Ltd) ("**MSL**") who is authorised and regulated by the Financial Conduct Authority ("FCA") in the United Kingdom (MSL and its affiliates are collectively referred to as "**MAYBANK**"). BOBCAPS is not authorized to directly distribute this research report in the UK.

This report has not been prepared by BOBCAPS in accordance with the UK's legal and regulatory requirements.

This research report is for distribution only to, and is solely directed at, selected persons on the basis that those persons: (a) are eligible counterparties and professional clients of MAYBANK as selected by MAYBANK solely at its discretion; (b) have professional experience in matters relating to investments falling within Article 19(5) of the Financial Services and Markets Act 2000 (Financial Promotion) Order 2005, as amended from time to time (the "Order"), or (c) fall within Article 49(2)(a) to (d) (high net worth companies, unincorporated associations, etc. as mentioned in the stated Article) of the Order; (all such persons together being referred to as "relevant persons").

This research report is directed only at relevant persons and must not be acted on or relied on by any persons who are not relevant persons. Any investment or investment activity to which this material relates is available only to relevant persons and will be engaged in only with relevant persons.

The relevant person as recipient of this research report is not permitted to reproduce, change, remove, pass on, distribute or disseminate the data or make it available to third parties without the written permission of BOBCAPS or MAYBANK. Any decision taken by the relevant person(s) pursuant to the research report shall be solely at their costs and consequences and BOBCAPS and MAYBANK shall not have any liability of whatsoever nature in this regard.

No distribution into the US:

This report will not be distributed in the US and no US person may rely on this communication.

Other jurisdictions:

This report has been prepared in accordance with SEBI (Research Analysts) Regulations and not in accordance with local regulatory requirements of any other jurisdiction. In any other jurisdictions, this report is only for distribution (subject to applicable legal or regulatory restrictions) to professional, institutional or sophisticated investors as defined in the laws and regulations of such jurisdictions by Maybank Securities Pte Ltd. (Singapore) and / or by any broker-dealer affiliate or such other affiliate as determined by Malayan Banking Berhad.

If the recipient of this report is not as specified above, then it should not act upon this report and return the same to the sender.

By accepting this report, you agree to be bound by the foregoing limitations.